semaglutide1 2resmetiromhepatocellular carcinomatype 2 diabetesMetabolic dysfunction-associated steatotic liver diseaseMASHmetabolic dysfunction-associated steatohepatitiscirrhosisliver failurenovel pharmacological therapies+1 more
…hepatocellular carcinoma. The recent approval of resmetirom and semaglutide1 2 for active, fibrotic MASH (F2–F3) highlights the urgent need fo…